D3-GHR Polymorphism and Turner Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

2005-05-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome.

Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Turner Syndrome Short Stature

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

recombinant human growth hormone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Turner syndrome defined by a structural aberration or lack of the X chromosome.
* Growth velocity less than 2 cm/year at the time of final analysis (= final height).

Exclusion Criteria

* Age \<3.5 or \>14 years at start of GH therapy,
* GH peak serum levels \< 8 ng/ml in two independent tests,
* Thelarche at start or during the first year of treatment,
* Oxandrolone therapy for any time and a duration of GH therapy less than 2 years.

Minimum Eligible Age

38 Months

Maximum Eligible Age

14 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gerhard Binder

Pediatric Endocrinology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Gerhard Binder, M.D. PhD

Role: PRINCIPAL_INVESTIGATOR

University-Children's Hospital Tübingen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University-Children's Hospital

Tübingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Dos Santos C, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet. 2004 Jul;36(7):720-4. doi: 10.1038/ng1379. Epub 2004 Jun 20.

Reference Type BACKGROUND

PMID: 15208626 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TS-TUE-FH1

Identifier Type: -

Identifier Source: org_study_id